Cargando…

Complement as a target in COVID-19?

There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients.

Detalles Bibliográficos
Autores principales:	Risitano, Antonio M., Mastellos, Dimitrios C., Huber-Lang, Markus, Yancopoulou, Despina, Garlanda, Cecilia, Ciceri, Fabio, Lambris, John D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Comment
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187144/ https://www.ncbi.nlm.nih.gov/pubmed/32327719 http://dx.doi.org/10.1038/s41577-020-0320-7

Ejemplares similares

Author Correction: Complement as a target in COVID-19?
por: Risitano, Antonio M., et al.
Publicado: (2020)

The first case of COVID-19 treated with the complement C3 inhibitor AMY-101
por: Mastaglio, Sara, et al.
Publicado: (2020)

Efficacy matters: broadening complement inhibition in COVID-19
por: Mastellos, Dimitrios C, et al.
Publicado: (2021)

Complement C3 vs C5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy
por: Mastellos, Dimitrios C., et al.
Publicado: (2020)

Complement-Dependent Mechanisms and Interventions in Periodontal Disease
por: Hajishengallis, George, et al.
Publicado: (2019)

Response to “Comment on Mastellos and colleagues and efficacy of complement-targeting drugs in COVID-19”
por: Mastellos, Dimitrios C., et al.
Publicado: (2021)

Editorial: Therapeutic Modulation of the Complement System: Clinical Indications and Emerging Drug Leads
por: Mastellos, Dimitrios C., et al.
Publicado: (2020)

Complement C3 inhibition in severe COVID-19 using compstatin AMY-101
por: Skendros, Panagiotis, et al.
Publicado: (2022)

Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction
por: Karasu, Ebru, et al.
Publicado: (2019)

Corrigendum: Targeting Complement Pathways in Polytrauma- and Sepsis-Induced Multiple-Organ Dysfunction
por: Karasu, Ebru, et al.
Publicado: (2019)

Safety and Efficacy of the Complement Inhibitor AMY-101 in a Natural Model of Periodontitis in Non-human Primates
por: Kajikawa, Tetsuhiro, et al.
Publicado: (2017)

In Vivo Role of Complement-Interacting Domains of Herpes Simplex Virus Type 1 Glycoprotein Gc
por: Lubinski, John, et al.
Publicado: (1999)

The opening salvo of anti-complement therapy against COVID-19
por: Campbell, Courtney M
Publicado: (2020)

Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics
por: Gavriilaki, Eleni, et al.
Publicado: (2019)

Complement and protection from tissue injury in COVID-19
por: Ortiz, Alberto
Publicado: (2020)

Complement C5a inhibition: a new form of COVID-19 treatment for mechanically ventilated patients?
por: Kalil, Andre C, et al.
Publicado: (2022)

COVID-19: risk for cytokine targeting in chronic inflammatory diseases?
por: Schett, Georg, et al.
Publicado: (2020)

Complement receptors C5aR1 and C5aR2 act differentially during the early immune response after bone fracture but are similarly involved in bone repair
por: Kovtun, Anna, et al.
Publicado: (2017)

COVID-19 cytokine storm: targeting the appropriate cytokine
por: Cron, Randy Q
Publicado: (2021)

Terminal Complement Activation Is Induced by Factors Released from Endplate Tissue of Disc Degeneration Patients and Stimulates Expression of Catabolic Enzymes in Annulus Fibrosus Cells
por: Kuhn, Amelie, et al.
Publicado: (2023)

Editorial: Interactions of Pentraxins and Complement in Infection, Inflammation, and Cancer
por: Ma, Ying Jie, et al.
Publicado: (2022)

Thinking inside the box: intracellular roles for complement system proteins come into focus
por: O’Brien, Rebecca M., et al.
Publicado: (2023)

Off-label therapy targeting pathogenic inflammation in COVID-19
por: Romani, Luigina, et al.
Publicado: (2020)

Is IL-6 a key cytokine target for therapy in COVID-19?
por: Jones, Simon A., et al.
Publicado: (2021)

Complexity of complement activation in sepsis
por: Markiewski, Maciej M, et al.
Publicado: (2008)

Brain Leukocytes as the Potential Therapeutic Target for Post-COVID-19 Brain Fog
por: Kazama, Itsuro
Publicado: (2023)

Medical and gastroenterological education during the COVID-19 outbreak
por: Barberio, Brigida, et al.
Publicado: (2020)

The Challenges and Promise of Complement Therapeutics for Ocular Diseases
por: Park, Dong Ho, et al.
Publicado: (2019)

COVID-19 pandemic in west Africa
por: Martinez-Alvarez, Melisa, et al.
Publicado: (2020)

Complementing the Cancer-Immunity Cycle
por: Pio, Ruben, et al.
Publicado: (2019)

The complement alternative pathway in paroxysmal nocturnal hemoglobinuria: From a pathogenic mechanism to a therapeutic target
por: Risitano, Antonio M., et al.
Publicado: (2022)

Anti-Complement Treatment in Paroxysmal Nocturnal Hemoglobinuria: Where we Stand and Where we are Going
por: Risitano, Antonio M
Publicado: (2014)

Understanding COVID-19 in Africa
por: Tessema, Sofonias K., et al.
Publicado: (2021)

Ulcer pressure prevention and opportunity for innovation during the COVID-19 crisis
por: Nani, Fernando Souza, et al.
Publicado: (2020)

Remdesivir for COVID-19 in Europe: will it provide value for money?
por: Dal-Ré, Rafael, et al.
Publicado: (2021)

Iloprost for COVID-19-related vasculopathy
por: Moezinia, Carine J, et al.
Publicado: (2020)

Porphyromonas gingivalis disturbs host–commensal homeostasis by changing complement function
por: Olsen, Ingar, et al.
Publicado: (2017)

HIV and COVID-19: juxtaposition of two pandemics
por: Nkengasong, John
Publicado: (2022)

Remdesivir for COVID-19: challenges of underpowered studies
por: Norrie, John David
Publicado: (2020)

Parathyroid surgery during the COVID-19 pandemic: Time to think about the “New Normal”
por: Montenegro, Fábio Luiz de Menezes, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ibgcjb4pfacaljhbpqhpmvqe46